CRF Inc., a global provider of electronic Patient Reported Outcomes (ePRO) and wireless data collection solutions for the Life Science Industry, announced the expansion of its world-class Clinical Advisory Board. Comprised of leading clinical and scientific experts, the Clinical Advisory Board will play an important role in providing specialist scientific and therapeutic advice for customers? clinical programs.
CRF INC. EXPANDS CLINICAL ADVISORY BOARD
- Respected clinical and scientific advisors provide scientific and therapeutic area expertise for customer clinical programs -
London, UK & Waltham, MA – June 18, 2008: CRF Inc., the leading global provider of electronic Patient Reported Outcomes (ePRO) and wireless data collection solutions for the Life Science Industry, today announced the expansion of its world-class Clinical Advisory Board. Comprised of leading clinical and scientific experts, the Clinical Advisory Board will play an important role in providing specialist scientific and therapeutic advice for customers’ clinical programs. In addition, the board will provide advice and guidance on the interpretation of the FDA’s Draft Guidance for the Industry on Patient Reported Outcomes and validation requirements.
“We are privileged to bring together experts from some of the leading clinical and research institutes around the world,” said Pamela McNamara, Chief Executive Officer at CRF Inc. “Each member of our Clinical Advisory Board brings a wealth of knowledge and experience that will be instrumental in assisting our customers with their clinical programs. We are thrilled to welcome these clinical and scientific experts to CRF.”
CRF’s Clinical Advisory Board is comprised of renowned thought leaders in the fields of instrument development; psychometric validation; clinical study design and execution; and patient behavior as well as expertise in specific therapeutic areas. Rachael King, CRF Inc. Vice President for European Operations chairs the Clinical Advisory Board. Ms. King has an MA in Pharmacology from Cambridge University (UK) and 12 years experience working for a major Pharmaceutical company plus 14 years in the ePRO space. The Clinical Advisory Board includes Nancy Kline Leidy, PhD from the United BioSource Corporation; Richard Lennox, PhD of Psychometric Technologies; Ville Ojanen, PhD of Cogiteq Ltd.; and Susan MacIntyre RN, BSN of US teaching and Research Institutions, NHS Research Centres specializing in Sleep and Neurology.
About CRF Inc.
CRF Inc. (CRF) is a leading global provider of electronic Patient Reported Outcomes (ePRO) and wireless data collection solutions for the Life Science Industry. Through innovative technology and a thorough understanding of drug development and mobile computing, the company is driving the change to safer and more efficient, paper-free clinical trials. CRF's technology has been used by more than 160,000 patients across 60 countries in 66 languages for 45 indications. The company has demonstrated one of the industry's highest patient compliance rates - an average 95 percent compliance through Phase I, II, III and IV clinical trials.
CRF's award-winning product, the TrialMax® suite, is a flexible and configurable ePRO technology that provides real-time patient monitoring, outstanding data accuracy and increased safety through compliance. The TrialMax® application’s unique features enable clinical trial sponsors to rapidly collect valuable data and conduct complex clinical trials with greater flexibility than other ePRO solutions. CRF's experience, combined with its dedication to achieving high quality and responsive customer service, has made the company one of the life science industry's most trusted partners. For more information, please visit www.crfhealth.com <http://www.crfhealth.com/> .
TrialCollector®, TrialIntegrator®, and TrialMax® are registered trademarks of CRF Inc. All rights reserved. TrialLibrary™, TrialManager™, TrialStudio™ and other CRF product references are either a trademark or service mark of CRF Inc. All other trademarks and/or service marks of any other company are the property of their respective owners.
###
Media Contacts
UK:
Rafi Cooper / Lucy Clark
Buffalo Communications
t. +44 (0) 20 7 292 8680
[email protected]
US:
Lisa Felice
t. +1 781 835 6539
[email protected]
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
FDA-Approved Gene Therapy Beqvez Shows Sustained Efficacy, Safety in Long-Term Hemophilia B Trial
April 17th 2025Beqvez (fidanacogene elaparvovec), an FDA-approved one-time gene therapy for hemophilia B, demonstrated sustained factor IX expression, low bleeding rates, and a favorable safety profile over long-term follow-up.